Exact Sciences Announces Contract with Anthem BlueCross of California
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Exact Sciences' (EXAS) Prelim. FY15 Revenue Light of Expectations; FY16 Outlook Reaffirmed
January 11, 2016 6:22 AM ESTExact Sciences Corp. (Nasdaq: EXAS) announced that the company completed approximately 38,000 Cologuard tests during the fourth quarter ended Dec. 31, 2015, generating approximately $14.0 million to $14.5 million in revenue. For the full year 2015, the company expects revenue to be approximately $39.0 million to $39.5 million, the result of completing approximately 104,000 Cologuard tests during its first full year of commercialization. Exact Sciences has not completed preparation of its financial statements for the quarter and full year. These revenue estimates are based on preliminary, unaudited data.
*** The Street sees FY15 revenue of $41 million.
"We saw strong demand for Cologuard and... More
